BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 23125082)

  • 1. Influence of gonadotropin-releasing hormone agonist on the effect of chemotherapy upon ovarian cancer and the prevention of chemotherapy-induced ovarian damage: an experimental study with nu/nu athymic mice.
    Lin QY; Wang YF; Weng HN; Sheng XJ; Jiang QP; Yang ZY
    J Zhejiang Univ Sci B; 2012 Nov; 13(11):894-903. PubMed ID: 23125082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of a GnRH agonist with an antagonist prevents flare-up effects and protects primordial ovarian follicles in the rat ovary from cisplatin-induced toxicity: a controlled experimental animal study.
    Li X; Kang X; Deng Q; Cai J; Wang Z
    Reprod Biol Endocrinol; 2013 Mar; 11():16. PubMed ID: 23452939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gonadotrophin-releasing hormone agonists for fertility preservation: unraveling the enigma?
    Hasky N; Uri-Belapolsky S; Goldberg K; Miller I; Grossman H; Stemmer SM; Ben-Aharon I; Shalgi R
    Hum Reprod; 2015 May; 30(5):1089-101. PubMed ID: 25796551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Study on the effects of gonadotropin-releasing hormone analogues in the inhibition of ovarian cancer transplanted tumors and in the protection of ovarian function after chemotherapy on nude mice].
    Zhang Y; Lu ZY; Yan XH; Wang JJ; Feng WW; Ding JX; Hua Kq
    Zhonghua Fu Chan Ke Za Zhi; 2011 Dec; 46(12):892-7. PubMed ID: 22333277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GnRH agonist leuprolide acetate does not confer any protection against ovarian damage induced by chemotherapy and radiation in vitro.
    Bildik G; Akin N; Senbabaoglu F; Sahin GN; Karahuseyinoglu S; Ince U; Taskiran C; Selek U; Yakin K; Guzel Y; Ayhan C; Alper E; Cetiner M; Balaban B; Mandel NM; Esen T; Iwase A; Urman B; Oktem O
    Hum Reprod; 2015 Dec; 30(12):2912-25. PubMed ID: 26466909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increase of antitumor activity of cisplatin using agonist of gonadotropin-realising hormone and inhibitor of aromatase on the model of ascites ovarian tumor.
    Tkalia IG; Vorobyova LI; Grabovoy AN; Svintsitsky VS; Tarasova TO; Lukyanova NY; Todor IN; Chekhun VF
    Exp Oncol; 2014 Sep; 36(3):184-90. PubMed ID: 25265352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective effects of mangafodipir against chemotherapy-induced ovarian damage in mice.
    Qin Y; Iwase A; Murase T; Bayasula ; Ishida C; Kato N; Nakamura T; Osuka S; Takikawa S; Goto M; Kotani T; Kikkawa F
    Reprod Biol Endocrinol; 2018 Oct; 16(1):106. PubMed ID: 30368246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feasibility and efficacy of gonadotropin-releasing hormone agonists for the prevention of chemotherapy-induced ovarian insufficiency in patients with malignant ovarian germ cell tumours (KGOG 3048R).
    Choi MC; Chung YS; Lee JW; Kwon BS; Park BK; Kim SI; Shim SH; Lee KB; Seong SJ; Lee SJ; Lee SH; Yoo HJ; Song T; Kim MK; Baek MH; Kang S; Kim YM
    Eur J Cancer; 2020 Jul; 133():56-65. PubMed ID: 32442924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dexamethasone inhibits the effect of paclitaxel on human ovarian carcinoma xenografts in nude mice.
    Hou WJ; Guan JH; Dong Q; Han YH; Zhang R
    Eur Rev Med Pharmacol Sci; 2013 Nov; 17(21):2902-8. PubMed ID: 24254559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protection against cisplatin-induced ovarian damage by the antioxidant sodium 2-mercaptoethanesulfonate (mesna) in female rats.
    Yeh J; Kim BS; Peresie J
    Am J Obstet Gynecol; 2008 Apr; 198(4):463.e1-6; discussion 463.e6-7. PubMed ID: 18395042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Protective effect of GnRH analogues on the reproductive capacity of women with neoplasia or autoimmune disease who require chemotherapy. Final results of a phase ii clinical trial].
    Gris-Martínez JM; Trillo-Urrutia L; Gómez-Cabeza JJ; Encabo-Duró G
    Med Clin (Barc); 2016 Feb; 146(3):97-103. PubMed ID: 26194532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of depot GnRH agonist on AMH levels in healthy reproductive-aged women.
    Su HI; Maas K; Sluss PM; Chang RJ; Hall JE; Joffe H
    J Clin Endocrinol Metab; 2013 Dec; 98(12):E1961-6. PubMed ID: 24081742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Influence of gonadotropin-releasing hormone agonist on the effects of chemotherapy upon ovarian cancer: an experimental study with rat model].
    Yuan GW; Shen K; Yang JX
    Zhonghua Yi Xue Za Zhi; 2005 Jun; 85(20):1428-31. PubMed ID: 16029659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ceramide-1-phosphate has protective properties against cyclophosphamide-induced ovarian damage in a mice model of premature ovarian failure.
    Pascuali N; Scotti L; Di Pietro M; Oubiña G; Bas D; May M; Gómez Muñoz A; Cuasnicú PS; Cohen DJ; Tesone M; Abramovich D; Parborell F
    Hum Reprod; 2018 May; 33(5):844-859. PubMed ID: 29534229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers.
    Liu G; Yang D; Rupaimoole R; Pecot CV; Sun Y; Mangala LS; Li X; Ji P; Cogdell D; Hu L; Wang Y; Rodriguez-Aguayo C; Lopez-Berestein G; Shmulevich I; De Cecco L; Chen K; Mezzanzanica D; Xue F; Sood AK; Zhang W
    J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25995442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of gonadotropin-releasing hormone analog on ovarian reserve in children with central precocious puberty.
    Tao Y; Si C; Li H; Han J; Hou H; Yang M
    Ann Palliat Med; 2020 Jan; 9(1):53-62. PubMed ID: 32005063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a prospective randomized trial.
    Demeestere I; Brice P; Peccatori FA; Kentos A; Gaillard I; Zachee P; Casasnovas RO; Van Den Neste E; Dechene J; De Maertelaer V; Bron D; Englert Y
    J Clin Oncol; 2013 Mar; 31(7):903-9. PubMed ID: 23129737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No Evidence for the Benefit of Gonadotropin-Releasing Hormone Agonist in Preserving Ovarian Function and Fertility in Lymphoma Survivors Treated With Chemotherapy: Final Long-Term Report of a Prospective Randomized Trial.
    Demeestere I; Brice P; Peccatori FA; Kentos A; Dupuis J; Zachee P; Casasnovas O; Van Den Neste E; Dechene J; De Maertelaer V; Bron D; Englert Y
    J Clin Oncol; 2016 Aug; 34(22):2568-74. PubMed ID: 27217453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A gonadotropin-releasing hormone agonist for the prevention of docetaxel-induced gonadal damage.
    Park I; Lee S; Ryu KJ; Min KJ; Hong JH; Song JY; Lee JK; Lee NW
    J Obstet Gynaecol; 2017 Aug; 37(6):783-789. PubMed ID: 28502234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progesterone decreases the extent of ovarian damage caused by cisplatin in an experimental rat model.
    Ozdamar S; Taskin MI; Onder GO; Kaymak E; Baran M; Yay A
    Adv Clin Exp Med; 2019 Jan; 28(1):25-33. PubMed ID: 30066501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.